Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02774434
Recruitment Status : Completed
First Posted : May 17, 2016
Last Update Posted : February 7, 2019
Sponsor:
Information provided by (Responsible Party):
Draeger Medical Systems, Inc.

Brief Summary:
The Canadian Pediatric Society recently published guidelines to monitor bilirubin levels and as part of standard of care all hospitalized newborns are routinely monitored for the development of high bilirubin or jaundice every 8-12 hours. One device approved and used in both Canada and the United States is the Draeger Jaundice Meter JM-103, a non-invasive medical device. It has been proven to be effective in patients >35 weeks gestational age. Recently the JM-103 has been upgraded to include a bigger touch screen, greater storage and functionality. The rest of the features of the JM-103 and JM-105 are identical. In order to test the accuracy of the JM-105 neonates from ≥ 24 weeks gestational age who have or have not undergone phototherapy will be prospectively monitored for transcutaneous bilirubin (TcB) using the JM-105. The measurements will be compared to a physician-ordered total serum bilirubin (TSB).

Condition or disease Intervention/treatment Phase
Hyperbilirubinemia Neonatal Jaundice Device: JM-105 Not Applicable

Detailed Description:

Hyperbilirubinemia is a condition that occurs in newborns when there is too much bilirubin in the blood. It is the most common cause of newborns being readmitted to the hospital. It may be harmless or harmful depending on what the cause is and how bad it is. The serum level of bilirubin required for jaundice varies with infants skin tones and body region, however jaundice usually becomes visible in the white part of the eye at smaller levels. Although jaundice in newborn is generally not harmful, it is important to monitor newborns to identify those that are at risk of developing a neurological dysfunction from high bilirubin levels. As part of standard of care all hospitalized newborns are routinely monitored for the development of jaundice by nursing staff and physicians every 8-12 hours. Although jaundice in newborns can usually be detected by lightening/whitening in the skin with digital pressure, this method of visual estimation is very inaccurate and unreliable. Transcutaneous bilirubin measurements are non-invasive and has proven to be equivalent to total serum bilirubin measurements. The JM-103 has been proven to be an effective TcB measure in ethnically diverse populations for patients >35 weeks gestational age. The JM-105 has been upgraded from the JM-103 with greater efficiency and accuracy. The basic function is the same but has been improved with a larger touch screen, data storage and transmission functionality.

This prospective multi-centre study will be conducted to determine the diagnostic accuracy and performance of the use of the JM-105 in providing transcutaneous bilirubin measurements to estimate serum total bilirubin in neonates ≥ 24 weeks of gestational age who have or have not undergone phototherapy. The study will compare each of the measurements of transcutaneous bilirubin (TcB) obtained for 10 days via the JM-105 device with a neonatology team-ordered series of serum total bilirubin (TSB) measured by high-performance liquid chromatography.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 464 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Efficacy Study of the Draeger Jaundice Meter (JM-105) in Providing TcB Measurements to Estimate TSB in Neonates of ≥ 24 Weeks of Gestational Age Who Have and Have Not Undergone Phototherapy
Actual Study Start Date : November 2016
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Jaundice

Arm Intervention/treatment
Experimental: JM-105
Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
Device: JM-105
Measurement of TcB via the JM-105 device




Primary Outcome Measures :
  1. Accuracy of TcB measured with the JM-105 device in predicting the Serum Bilirubin measurements performed on blood samples [ Time Frame: Within 15 minutes of blood sample taking ]
    Primary objective is to determine the accuracy of TcB measured with the JM-105 device in predicting the Serum Bilirubin measurements performed on blood samples from heel sticks or from peripheral line in neonates ≥ 24 weeks of gestational Age who are currently undergoing or have undergone phototherapy as a Screening and Monitoring device for hyperbilirubinemia


Secondary Outcome Measures :
  1. Normalized curve of TSB measurements using the JM-105 [ Time Frame: Within 15 minutes of blood sample taking ]
    The secondary objective is to determine a normalized curve of TSB measurements using the JM-105.

  2. Influence of phototherapy on TSB measurements [ Time Frame: Within 15 minutes of blood sample taking ]
    The Impact of phototherapy on TSB measurements will be explored.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   24 Weeks to 40 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is a neonate ≥24 weeks of gestational age for whom a course of phototherapy has not started, is in progress or has been completed
  • The subject's routine management includes TSB evaluations
  • The subject's family are willing and able to participate in baseline and TSB measurements over 10 days
  • Written informed consent to participate in the study has been provided by the subject or legal representative (parent or legal guardian in a clinical study involving children)

Exclusion Criteria:

  • The subject has Hydrops fetalis
  • The subject has major congenital malformations, diseases or skin conditions or thickness that, in the opinion of the investigator would preclude or interfere with the use of the JM-105

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774434


Locations
Layout table for location information
Canada, Ontario
Saint Michael's Hospital
Toronto, Ontario, Canada, M5B1W8
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Hamilton Health Science Centre
Toronto, Ontario, Canada
Sponsors and Collaborators
Draeger Medical Systems, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Michael Sgro, MD St. Michael's Hospital, Toronto

Layout table for additonal information
Responsible Party: Draeger Medical Systems, Inc.
ClinicalTrials.gov Identifier: NCT02774434     History of Changes
Other Study ID Numbers: JM-105 Study
First Posted: May 17, 2016    Key Record Dates
Last Update Posted: February 7, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Jaundice
Hyperbilirubinemia
Jaundice, Neonatal
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Hyperbilirubinemia, Neonatal
Infant, Newborn, Diseases